Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 3/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30733428 | 0.84 | HDAC1 (0.55) | P2RY1HDAC1HDAC6HDAC8FFAR1 | |
| SCHEMBL23289929 | 0.79 | HDAC1 (0.64) | P2RY1HDAC1HDAC6HDAC8FFAR1 | |
| SCHEMBL30733439 | 0.77 | FFAR1 (0.51) | P2RY1HDAC1HDAC6HDAC8FFAR1 | |
| SCHEMBL5578630 | 0.77 | OPRM1 (0.57) | P2RY1MAPTNPY5R | |
| SCHEMBL30733409 | 0.76 | HDAC1 (0.59) | P2RY1HDAC1HDAC6HDAC8FFAR1 | |
| SCHEMBL5578971 | 0.76 | SIGMAR1 (0.48) | P2RY1HDAC1HDAC6MAPTNPY5R | |
| SCHEMBL30733432 | 0.74 | HDAC1 (0.47) | HDAC1HDAC6HDAC8FFAR1NPY5R | |
| SCHEMBL30733410 | 0.73 | HDAC1 (0.58) | P2RY1HDAC1HDAC6HDAC8FFAR1 | |
| SCHEMBL13309551 | 0.72 | HDAC1 (0.56) | P2RY1HDAC1HDAC6HDAC8FFAR1 | |
| SCHEMBL5578994 | 0.71 | MAPT (0.48) | P2RY1MAPTNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | P2RY1 68/4885HDAC1 2067/4885HDAC6 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.